Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
Status:
Recruiting
Trial end date:
2028-04-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of stereotactic radiosurgery and pembrolizumab in
treating patients with meningioma that has come back (recurrent). Stereotactic radiosurgery
is a type of external radiation therapy that uses special equipment to position the patient
and precisely give a single large dose of radiation to a tumor. It is used to treat brain
tumors and other brain disorders that cannot be treated by regular surgery. Pembrolizumab is
a humanized monoclonal antibody. An antibody is a common type of protein made in the body in
response to a foreign substance. Antibodies attack foreign substances and protect against
infection. Antibodies can also be produced in the laboratory for use in treating patients; an
antibody that is made in the lab is also known as a humanized monoclonal antibody.
Pembrolizumab is a highly selective humanized monoclonal antibody that is designed to block
the action of the receptor PD-1. It has been studied in lab experiments and in other types of
cancer. The PD-1 receptor works to keep the immune system from noticing tumor cells. The
addition of pembrolizumab to stereotactic radiosurgery may improve the progression free
survival of patients with meningioma.